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ABSTRACT 
This work is a business plan to evaluate an anti-epilepsy drug development 
technology that has commercial potential to be used as a high throughput screening 
method.  Epilepsy is such a prevalent neurological disorder that it affects over 1% of the 
general population worldwide.  The anti-epilepsy drug (AED) market is in its steady 
growth along with the high throughput screening (HTS) market, as many biotech and 
pharmaceutical companies take a disintegrated value chain approach in order to capture 
more value during the drug development process, which could take over 10 years and 
cost up to $1 billion.   After extensive market research and financial analyses, it is found 
that the technology could spawn a business that could generate $15 million per year with 
an outstanding IRR of 72% for the first wave of investors.   
 
Keywords: (AED, epilepsy, High Throughput Screening, Technology, Valuation). 
 
Subject Terms:  Business Plan 
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EXECUTIVE SUMMARY 
C-Motions’ breakthrough anti-epilepsy drug high throughput screening 
technology is likely to produce rapid growth of shareholder value, leveraging a small 
amount of equity capital to grow by $15M/year, and the company is likely to become a 
highly profitable business within six years with an exceptionally high net margin of 32%.  
C-Motions’ business has outstanding characteristics: 
• An exclusive $200 million potential world market, currently underpenetrated due 
to the limitation of existing technologies that C-Motions’ Anti Epilepsy Drug 
(AED) High Throughput Screening (HTS) service overcomes. 
• A well fitted, compelling solution to the high cost of the AED development by 
biotech and pharmaceutical companies worldwide. 
• Capable management team combining scientific, engineering and business 
expertise. 
• Easily targeted major customers in the biotech industry with a history of early 
technology adoption. 
• Potential of generating recurring revenues from high-margin sales, and resulting 
high-volume sales of the consumables from the next generation of product 
development. 
• Small capital requirements relative to market size. 
• Potential for profitable exit through sale of company or IPO within seven years. 
C-Motions’ technology will focus on solving a high cost problem for biotech and 
pharmaceutical companies during drug development.  A rodent model is a gold standard 
for testing toxicity and efficacy of a potential AED candidate.  A rat or a mouse is 
prepared for up to two weeks to induce epileptic seizure in the animal.  In order to test the 
 Confidential v 
candidate drug, a researcher or technician would inject the drug candidate into the 
prepared animal each time, following extensive monitoring of its behaviours.  Due to 
required person-hours and before/after-cares for the animals used, the model is 
extensively used only in the later stage of the AED development during the preclinical 
drug development stage.  On the other hand, HTS, a new innovative way to develop 
potential drug candidates with the least amount of time and resource, is capable of 
selecting candidate drugs in the early stage of the preclinical drug development.  C-
Motions’ technology exploits the potential gap between the in vitro (existing HTS) and in 
vivo (animal model) stages of the AED development, allowing an early stage animal HTS 
to measure the efficacy and toxicity of AED candidates.  C-Motions’ management team 
is bound to bridge the current industry gap between the demands and technology, and 
build a $15M/year business within six years. 
More than 600 million people worldwide have been or will be diagnosed with 
epilepsy in their lifetimes, which imposes a  burden of $25 billion/year on the health care 
system in the US alone.  Each year, biotech and pharmaceutical companies worldwide 
spend over $77B for new drug R&D in total, with the amount of bringing a new 
generation of AEDs reaching conservatively $500M/year.  C-Motions’ technology can 
expedite these AED discovery efforts by biotech and pharmaceutical companies, 
providing a fast, reliable and a new golden standard, appropriate for use by both biotech 
and pharmaceutical companies, as well as by contract research organizations (CROs).   
C-Motions’ initial strategy will focus on adoption of its technology by taking on a 
CRO business model, which appeals to potential customers who are actively looking for 
ways to save the AED development cost while pursuing quality R&D.  C-Motions’ 
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business model also allows the potential customers an easier entry to the AED HTS as 
they can pay for the company’s service without purchasing a potentially costly platform 
for their budgets.  Meantime, because C-Motions sells mostly data and information 
without incurring significant cost-of-goods-sold, the sales of the service will bring the 
company an exceptionally high net margin of 32%. 
C-Motions’ marketing will focus on key opinion leaders within the fields of the 
AED development community in order to gain respected industry referrals.  These 
influences will push other biotech and pharmaceutical companies to use C-Motions’ 
services, while the company’s dedicated direct sales force team will target these 
customers in multiple approaches by visiting and/or calling them as well as attending 
relevant conferences to promote and facilitate adoption of the technology.  Once 
significant market penetration has been achieved, C-Motions will seek a partnership with 
a major biotech or pharmaceutical company to provide a tailored AED HTS for the 
partnered company.  That could lead the vertical integration of C-Motions’ AED HTS 
Platform through M&A as an early exit option.  Another possible scenario would be 
development of the AED HTS platform that can be sold to biotech and pharmaceutical 
companies who wish to operate the AED HTS in-house.  In that case, C-Motions will 
adopt a ‘razor-blade’ strategy by selling consumables that allows capturing value for both 
the customers and C-Motions.   
Currently C-Motions seeks $500K seed investment to fund product development.  
Two subsequent venture rounds of $1.5M and $2.5M will fund commercialization and 
marketing of the technology.  C-Motions offers a unique opportunity to the investors, 
who would like to enjoy an outstanding 72% IRR from a projected service and product 
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sales with liquidity within six years.  The company is looking for sophisticated, 
experienced investors to join this opportunity. 
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GLOSSARY 
ADME/Tox Absorption, Distribution, Metabolism, Excretion and Toxicity 
AED Anti Epilepsy Drug 
Anteromesial A part of the brain where groups of neurons are located in 
complex vertebrates, including humans; the anteromesial 
temporal lobe is also known as amygdale 
CEO Chief Executive Officer 
cGLP Current Good Laboratory Practices 
COO Chief Operations Officer 
Corpus callosotomy A surgical procedure that disconnects the cerebral hemispheres, 
which splits the left and right parts of the brain 
CRO Contract Research Organization 
CSO Chief Scientific Officer 
CTO Chief Technology Officer 
EBITDA Earnings Before Interest, Taxes, Depreciation and Amortization 
Efficacy Ability to bring a desired effect 
Electrography A process of using chemically induced electric current to 
produce images and signals 
Epileptiform A stage that resembles epilepsy or its manifestations, such as 
seizures 
FDA The US Food and Drug Administration 
Gold standard In medical science, it is a test or a procedure that is considered 
definitive 
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Hepatotoxicity Degree of destructiveness to the liver 
Hit-to-candidate Drug development process that uses iterations between 
chemistry and biology to find a right drug candidate 
HTS High Throughput Screening 
In silico Through computer based calculations or simulations 
In vitro Through a controlled environment outside of a living organism 
(e.g. in a test tube) 
In vivo Through a living organism 
Intravenous Within a vein 
IPO Initial Public Offering 
IRR Internal Rate of Return 
Lesionectomy An operation to remove a lesion – a damaged or abnormally 
functioning area – in the brain 
Liquidity Ability to sell/buy an asset with causing a significant change in 
the price or value 
Lobotomy A medical procedure involving incision into a lobe 
LT Long Term 
LTM Last Twelve Months 
M&A Merger and Acquisition 
Monotherapy A therapy that consists of only one drug 
Neonate A newborn infant (usually less than four weeks old) 
Neurotherapeutics Therapeutic treatments for psychological, psychiatric, and 
nervous disorders 
NMEs New Molecular Entities 
NPV Net Present Value 
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Pharmacodynamics A study of what a drug can do to an organism 
Pharmacokinetics A study of what an organism can do to a drug 
PhRMA The Pharmaceutical Research and Manufacturers of America 
Pre-clinical Before clinical studies in drug development 
Pro forma Latin: as a matter of form; in business, a pro forma document 
shows actual transactions 
PTZ Pentylenetetrazol 
PV Present Value 
R&D Research and Development 
ROA Return On Assets 
ROE Return On Equity 
S&T Science and Technology 
SOP Standard Operating Procedure 
SR & ED Scientific Research & Experimental Development 
Subpial transection A surgical procedure that involves a series of shallow cuts in 
the brain tissue in order to control neurological disorders, 
especially epilepsy 
SWOT Strength-Weakness-Opportunity-Threat 
Temporal A part of the brain that is involved in speech, memory, and 
hearing functions 
Tolerability A degree to which an exposed organism can resist a drug 
Toxicity A degree to which a drug can damage an exposed organism 
UILO University Industry Liaison Office 
Vagus Nerve 
Stimulation (VNS) 
VNS is a treatment for certain types of epilepsy and depression.  
It uses a stimulator that sends electric impulses to the left vagus 
nerve n the neck via an implanted electrode under the skin 
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1:  THE ANTI EPILEPSY DRUG INDUSTRY 
1.1 What is Epilepsy? 
Epilepsy is a common brain disorder that affects an estimated 1-2% of the general 
population, and is the second most common serious neurological condition in the United 
States after stroke.  Epilepsy imposes an annual economic burden of approximately $25 
billion in the US, mainly due to health care costs and lost productivity.  According to the 
National Institute of Neurological Disorders and Stroke, it is important to begin treatment 
as soon as possible after diagnosis of epilepsy.1  With help of modern medicine and 
surgical techniques, for about 80 percent of the patients, epileptic seizures can be 
managed.  Left untreated, however, the disease can cause significant morbidity and even 
mortality. 
In recent years, epilepsy has become highly treatable with the advent of modern 
medicines.  Epilepsy has received a great deal of attention from the health sector and 
related industries because: 
• Epilepsy is such a common disease 
• It is a very misunderstood disease despite its common occurrence 
• The social impacts of the disease on its victims are significant. 
                                                 
1 http://www.ninds.nih.gov/disorders/epilepsy/epilepsy.htm 
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As a result, the drug, diagnostics, and surgical operations industries have been rapidly 
moving forward to treat (and ultimately cure) the affected in order to bring a better 
quality of life. 
1.2 Available Epilepsy Treatments 
1.2.1 Anti Epilepsy Drug Treatment 
Epilepsy is not a disease that can be cured solely using pharmacologic approaches 
at this moment.  Therefore, the main objective of drug therapy for epilepsy has been, and 
is going to be (for a while), to control the frequency and severity of epileptic seizures.  
Since the critical mechanism of epilepsy has not been fully understood so far, each 
patient must often undergo extensive period of drug and dose adjustment to find the 
proper therapeutic regimen. 
Table 1-1 shows commonly used anti epilepsy drugs (AEDs) in the market.  
According to market research2, Topamax was the leading epilepsy drug in 2005 with 
sales of US$1.7 billion followed by Lamictal and Depakote.  However, all three AEDs 
became generic as of 2008, which reduced sales revenues drastically (more updated 
details are in Chapter 4).  To date, no large-scale clinical studies have been conducted to 
establish superiority of the available drugs in the market including older drugs used by 
the health practitioners.  In addition, many commercially available drugs have been 
introduced since the 90s, indicating there are unmet needs for advanced treatment for the 
epilepsy patients.   
                                                 
2 “CNS Market Trends, 2007 to 2010: Key market forecasts and growth opportunities” by The PharmYard 
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One of the key issues for a new anti epilepsy drug is the use in neonates and 
younger children, who require extensive pharmacokinetic, tolerability, and efficacy 
studies because age is a significant factor in determining anti epilepsy drug toxicity and 
clearance.  For example, children will be less tolerant to hepatotoxicity caused by 
administration of valproic acid. 
Another trend for AED is putting new packages on older drugs with improved 
dosage regime.  For example, carbamazepine and divalproex sodium are now available in 
time-release controlled formulations, which reduce the numbers of daily doses.  Valproic 
acid is now available as an intravenous preparation to increase its efficacy.   
Table 1-1 Commonly Used AEDs in the Market 
Drug Brand Name(s) Company
Carbamazepine Carbatrol®      
Tegretol®
Shire US  
Novartis
Divalproex Depakote® Abbott
Felbamate Felbatol® Wallace
Gabapentin Neurontin® Pfizer
Lamotrigine Lamictal® GlaxoSmithKline
Levetiracetam Keppra® USB
Oxcarbazepine Trileptal® Novartis
Phenytoin Sodium Dilantin®           
generics
Pfizer           
Elkins-Sinn           
Mylan
Pregabalin Lyrica® Pfizer
Primidone Mysoline® Elan
Tiagabine Gabitril® Abbott
Topiramate Topamax® Ortho-McNeil
Valproic Acid Depakene®          
generics
Abbott         
Watson
Zonisamide Zonegran® Elan  
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1.2.2 Surgical Treatment 
Although many epilepsy patients opt for drug treatment, surgery remains a 
potential treatment.  Many health practitioners, however, agree that surgery should be 
considered as a treatment of last resort due to its potential risks involved.  In general, a 
patient must have disabling seizures after being treated with two or more serial 
monotherapy AEDs, which did not show any improved efficacy after maximum dosages.  
The probability of monotherapy or combination therapy being effective to this patient 
group is usually lower than 10% ("Collaborative Group for the Study of Epilepsy", 1992; 
Kwan & Brodie, 2000). 
The various surgical treatments for epilepsy include resection (temporal 
lobotomy), lesionectomy, subpial transection, corpus callosotomy, and vagus nerve 
stimulation.  Among these treatments, anteromesial temporal lobotomy has been the most 
commonly performed procedure resulting in approximately 70% success rate.  As 
mentioned, however, all the surgical options bear their risks, which can be irreversible, 
even life threatening in some cases. 
1.3 Current Unmet Needs for AEDs 
It is a fact that the world needs a better AED that reaches a wider range of patients.  
Despite advances in the AED research in recent years, approximately 20 to 30% of 
patients still suffer from epileptic seizures due to limitation of AED treatment.  In 
addition, in developed parts of the world, there are increasing number of epilepsy patients 
among the elderly, for reasons not fully understood (Sander, 2003).  The risk of 
developing epilepsy is estimated to be 1% from birth to age 20 years; however, the risk 
increases to 3% at age 75 years.  With a significant growth of the aging population in 
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developed countries, the prevalence of epilepsy will be significantly increasing in the 
near future.  The US AED market alone was $3.2 billion in 2006 with a steady growth 
rate, indicating that biotech and pharmaceutical companies could contribute to bring a 
better treatment for epilepsy to the world. 
In addition, as of January 31st, 2008, the FDA issued a sobering warning that 
states that the risk of suicide and suicidal behaviour could double for patients taking 
AEDs.3  In the current market, many AEDs are also prescribed for pain and psychiatric 
illnesses.  Some of the drugs are blockbusters such as Lyrica (Pfizer), which sells about 
$1.2 billion US per year.  This indicates that the current market could generate even 
greater demands for the next generation of AEDs. 
                                                 
3 U.S. Food and Drug Administration, FDA News, January 31, 2008. 
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2:  COMPANY, MANAGEMENT TEAM, AND PRODUCT 
2.1 Company Description 
C-Motions (read as See-Motions) is a Vancouver based biotech platform 
development and related services company that is developing an innovative drug 
development platform that will expedite drug development process.  C-Motions is 
currently proving the concept of the AED screening animal model, which will serve as a 
proprietary AED development platform for biotech and pharmaceutical companies who 
are actively searching for a better epilepsy treatment.  Available methods of testing 
efficacy of AED require extensive preparations of animals in order to induce chronic 
epilepsy in the animals.  In order to facilitate introduction of the platform, C-Motions will 
commence a service based business model for the biotech and pharmaceutical companies 
who are into AED Research and Development (R&D). 
2.2 Management Team 
C-Motions’ focused strategy will be executed by a management team with diverse 
backgrounds in science, engineering and business.  The followings are the profiles of the 
co-founders of C-Motions Biotechnology: 
JS Joseph Lee, PhD is a co-founder of C-Motions and the current Chief Operating 
Officer (COO).  He received his Ph.D. and held postdoctoral fellowship from the 
University of British Columbia. He has a variety of experience in different industries 
before he started his higher education and academic career, including sales, and small 
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business.  In his academic career, his research interests were liquid crystals, controlled 
drug release, cellulose, molecular sieves, fuel cell and polymeric materials for the 
chemical industry. Dr. Lee is currently an MBA candidate at Simon Fraser University, 
specializing in Biotechnology within the Management of Technology program.   
Sesath Hewapathirane is a co-founder of C-Motions and the current Chief Scientific 
Officer (CSO).  He received his MSc from the University of Toronto in the field of 
Pharmacology, where he gained extensive exposure to drug development research.  He 
has extensive experience in epilepsy research.  Mr. Hewapathirane is currently a PhD 
candidate under the supervision of Dr. Kurt Haas, who is a leading biomedical researcher 
in the field of brain diseases, in Neuroscience at the Brain Research Centre, University of 
British Columbia, working on the verification of the albino Xenopus laevis tadpole model 
for AED candidate screening. 
Kelly Sakaki is a co-founder of C-Motions and the current Chief Technology Officer 
(CTO) of the company.  He received his MSc from the University of Victoria.  Kelly 
Sakaki is a member of the Laboratory of Applied Control and Biorobotic Systems 
(LACOBS) under the supervision of Dr. Edward Park. He is currently completing a Ph. D. 
in Biomedical Engineering through the faculty of Mechanical Engineering. He has a 
Bachelors Degree in Computer Systems Engineering and a Diploma in 
Telecommunications Engineering Technology. He has been involved in the mechanical 
and electrical design of biomedical instruments, and robotics for the past four years, and 
has recently designed and fabricated the Biological Cell Manipulator (BCM) for the 
autonomous injection of cells. He has a strong understanding and experience in the 
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design and development of electromechanical systems, computer vision and significant 
experience working with cells at the discrete level.   
C-Motions is currently seeking inspirational, industry-experienced board members who 
will guide the company to the next phase of the business venture. 
2.3 Product Description 
Figure 2-1 shows rodent models of chronic epilepsy, which are known as the 
“gold standard” in AED research.  The models require the animals to go under proper 
care and maintenance following current Good Laboratory Practices (cGLP), not to 
mention the recurring cost of the animals for a larger group study.  Cost of burden 
extends to the research staff who would prepare the animals, which should add significant 
overhead cost to the already strenuous R&D budget for a small biotech company.  In 
addition, it takes weeks (14 ~ 30 days) to induce epilepsy in rodent models using 
chemical triggers, which are still manageable periods but not so desirable while testing 
efficacy in thousands of potential AED candidates. 
C-Motions’ AED Screening Platform technology, which uses an albino Xenopus 
tadpole (Figure 2-2) model, can screen efficacy of potential AEDs quickly and accurately 
using a proprietary visual tracking protocol for the following reasons: 
• The cost of the tadpole is a fraction to those of rodent animals, not to mention 
easy breeding and following maintenance regiments of the species.  Usually one 
breeding colony of a pair of Xenopus frogs can produce thousands of tadpoles that 
are ready in a couple of weeks after hatching from the eggs. 
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• The growth pattern of the tadpole that exhibits weeks of juvenile period is 
beneficial to study childhood epilepsies in humans, which are related to the still 
developing brains. 
• Easy preparation and low footwork of the tadpole model allow a high throughput 
platform, which expedites the AED candidate screening process. 
• Seizure induction using chemical triggers in the tadpoles occurs within minutes 
(as short as 10 minutes) as opposed to weeks in the rodent models. 
2.3.1 Scientific Basis 
It is known that the immature brain is exceptionally susceptible to seizures.  The 
current research of the Haas research group in the UBC Neuroscience Department 
focuses on a novel in vivo model system of developmental seizures based on the 
transparent albino Xenopus laevis tadpole, which allows direct examination of seizure 
activity, and seizure induced effects on neuronal development within the intact 
unanesthetized brain.  The chemical triggers used are pentylenetetrazol (PTZ), kainic 
acid, bicuculline, picrotoxin, 4-aminopyridine, and pilocarpine, which are known to 
induce seizure in tadpoles (Baraban, 2007).  All six compounds induce convulsive 
motions in the tadpoles depending on their dosages, which are typical behaviours in 
epileptic seizures.  A further study (Hewapathirane, Dunfield, Yen, Chen, & Haas, 2008) 
using PTZ has characterized that the convulsive motions (Figure 2-2) are indeed identical 
to the epileptiform electrographic responses, which can be stopped by valproate, a 
commonly used AED in human patients.  Detailed description of the experimental 
procedures and results will be published in a reputable journal (currently in press).   
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2.3.2 Proof of Concept 
Currently C-Motions is testing proof of concept in the AED Screening Platform 
for an automated process using a camera system and in-house developed motion 
detection software.  The current apparatus can capture the tadpoles in motion before and 
after exposure to PTZ and AEDs.  The algorithm for the convulsive motion detection in 
epileptic seizures of tadpoles is currently under development in the Engineering 
Department at the University of Victoria.   
2.3.3 Regulatory Compliance 
In order for C-Motions’ Platform to be used for drug discovery phase, it must 
follow current Good Laboratory Practices (cGLP) guidelines.  CGLP is a basic quality 
system concerned with the organizational process and the conditions under which non-
clinical health and environmental safety studies are planned, performed, monitored, 
recorded, archived and reported.  C-Motions’ Platform should be considered as both 
testing facility and equipment; the platform will have the capability of following Standard 
Operating Procedures (SOPs) that are approved by the testing facility management team, 
have a change control system that reflects Quality Assurance of the research, and be able 
to indicate identity, strength, purity and composition of each experimental batch. 
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Figure 2-1  Typical schematic of the rodent models for the study of chronic epilepsy used in many 
AED research laboratories 
 
 
 
Figure 2-2  A typical ‘C’ shaped convulsive motion of albino Xenopus tadpole due to epileptic seizure 
after the PTZ exposure   
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3:  MARKET ANALYSIS AND OPPORTUNITY 
3.1 World AED Market Overview 
According to the National Institute of Health, epilepsy affects 2.5 million people 
with 200,000 new cases a year in the US alone.  Although about 75% of those affected 
can be treated with existing AEDs to achieve seizure control, the rest are still waiting for 
better treatments.  The world neurotherapeutics market for epilepsy was $3.05 billion in 
2002 and is estimated to be $5.21 billion in 2010.4  The world market potential for AED 
has been steadily growing at about 7% compounded annually since 20015, which is the 
highest growth among the neurotherapeutic drugs.   
3.1.1 Notable AED R&D Efforts  
Approximately a dozen companies have been or are developing AEDs worldwide 
(as of August 2008).  Notable companies with their developmental AEDs are6: 
• Abbott (Depakote®, Approved by FDA) 
• Cephalon, Inc. (Gabitril®, Approved by FDA as an anti-convulsive 
medication) 
• D-Pharm Ltd. (DP-VPA, In Phase 2) 
• Eisai (Rufinamide, Submitted to FDA) 
• Elan Corporation plc (Zonegran®, Approved by FDA) 
                                                 
4 “The World Market for Neurotherapeutic Drugs”, August 2002 by MarketResearch.com 
5 Source: Kalorama Information 
6 Sources: Company websites 
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• NPS Pharmaceuticals, Inc. (NPSP156, Preclinical) 
• Neurologix, Inc. (NLX-E201, Preclinical) 
• Neuromed (T-type calcium channels blockers, In Discovery) 
• Parke-Davis, Now Pfizer (Cerebyx®, Approved by FDA) 
• Pfizer (Lyrica®, Approved by FDA) 
• Shire Pharmaceuticals Group plc. (Carbatrol®, Approved by FDA) 
• UCB SA (Keppra®, Approved by FDA; Brivaracetam, In Phase 3) 
• Valeant Pharma (Epilepsy Discovery Program, Discovery/Pre-Clinical; 
Diastat® NS, In Phase 1; Retigabine, In Phase 3) 
3.1.2 AED Worldwide Market Shares 
There are four popular prescription AEDs in the market as of 2007.  Table 3-1 
shows the AED market share worldwide for the non-generic drugs.  Among those, 
Depakote® lost its patent protection on January 29, 2008, which will significantly 
influence its sales by Abbott Laboratories.  In addition, all the four drugs are included in 
the list of the FDA that alerts risk of suicidal thoughts and behaviour with AEDs.  An 
interesting fact to notice would be that all the popular epilepsy drugs have more than 
single indications, which could bring bigger motivation to develop a new generation of 
AEDs.  For C-Motions, the companies that are actively searching for new AEDs will be 
the primary target for marketing the AED HTS service.   
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Table 3-1  Four Popular Non-generic AEDs: Their Market Shares and Indications7 
Non-generic 
Drugs Company
2007 Sales 
Worldwide 
(million)
Prescribed for
Depakote®* Abbott $1,580 Epilepsy, chronic pain, migraine headaches
Lyrica® Pfizer $1,580 Partial seizures, neuropathic pain
Keppra® UCB $1,500 Epilepsy, occasionally neuropathic pain
Lamictal®** GlaxoSmithKline $588 Epilepsy, bipolar disorder  
* Depakote® became generic in 2008 
** Since 2005, Lamictal® has been sold as generic in the US and Canada only for low dosage tablets (5 mg 
and 25 mg) 
 
3.1.3 Global AED Market Analysis 
Most of the  profit from AED sales comes from the seven major world healthcare 
markets, which are the USA, Japan, Germany, France, Spain, the UK and Italy.  Table 
3-2 and Figure 3-1 show the market potential for the seven countries, showing that the 
USA has the highest market potential followed by Japan by 2010.  Thus, it is also 
imperative for C-Motions to recognize the motivation behind the new AED development 
worldwide, and the company’s strategy will be focused according to the geographical 
presence of the biotech and pharmaceutical companies that develop AEDs.   
 
                                                 
7 Sales figures compiled with the companies’ financial data from CoreReference and the US Securities and 
Exchange Commission. 
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Table 3-2  Market Potential for the Seven Major World Healthcare Markets8 
Country 2001 AED Sales (in Billions)
2010 Estimated AED 
Sales (in Billions)
USA $1.17 $2.24
Japan $0.51 $0.94
Germany $0.31 $0.54
France $0.23 $0.41
UK $0.23 $0.41
Italy $0.23 $0.39
Spain $0.17 $0.29  
Figure 3-1  Market Potential Comparison between 2001 and 2010 for the Seven Major Markets9 
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3.2 Today’s Drug Development Process in General 
Drug development process is long and costly (Figure 3-2).  In any given year, the 
FDA approves about 90 drugs, among which only few reach the blockbuster stage, where 
the drug has sales over $1 billion.  A typical drug development cost reaches hundreds of 
millions and is steadily rising.  Many pharmaceutical companies are spending about 20% 
of the revenue for R&D to look for a next blockbuster, with global R&D spending 
estimated to be over $77 billion in 2007 (See Table 3-3).  A recent trend is that 
                                                 
8 Table created by author with data from “The World Market for Neurotherapeutic Drugs”, August 2002 by 
MarketResearch.com 
9 Chart created by author from Table 3-2. 
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pharmaceutical companies get involved in the later stages of drug development process 
whereas the early stages are carried by biotech companies.  Transferring the drug 
development process from one company to another can cause various degrees of 
disruptions and risks, which could be an opportunity for some.  Recently, many 
companies are exploring possibilities to maximize values of the drug development 
process by positioning themselves in different parts of the value chain.  A typical 
example is the case of Xenon Pharmaceuticals, a Burnaby-based biotech company that 
focuses on capturing value in the clinical data of drug development.10 
Table 3-3  Global R&D Spending by Biotech and Pharmaceutical Companies in 1996 – 200711 
Year Global R&D Spending (in billions) Growth Rate
1996 $35.3
1997 $36.8 4%
1998 $38.9 6%
1999 $40.2 3%
2000 $41.8 4%
2001 $44.8 7%
2002 $48.4 8%
2003 $52.3 8%
2004 $57.3 10%
2005 $63.4 11%
  2006 (Estimated) $70.0 10%
  2007 (Estimated) $77.3 10%  
 
3.2.1 Drug Discovery Process 
In drug development, the drug discovery process is typically the most lengthy and 
costly period (Figure 3-2; Figure 3-3), which requires many iterative cycles between 
                                                 
10 Simon Pimstone, CEO and founder of Xenon Pharmaceuticals commented that many biotech companies 
are moving from genomics to human (clinical) data, during the lecture of BUS776 SFU MOT in 
Summer 2008. 
11 Table created by author, with data source: CMR International and Kalorama Information 
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chemistry and biology.  Nowadays, drug discovery requires both target-based and 
chemistry-based technologies, which calls for many different types of technical expertise 
in the areas of molecular biology, high throughput screening, molecular and behavioural 
pharmacology, and combinatorial, medicinal and analytical chemistry.  Therefore, 
carrying over the entire drug discovery process would be a major challenge, especially, 
for a small biotech company, which typically has a limited amount of budget, and, hence, 
needs focused operations. 
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Figure 3-2  Stages of Drug Development with Numbers of Drug Candidates Tested at Each Stage 
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Figure 3-3  A Typical Budget Allocation in R&D12 
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12 Chart created by author with data from “Health’s Price Tag,” The Boston Globe, March 28, 2001, p. D4.  
The diagram shows the allocation of $26 billion in research and development by the US drug companies 
in 2000. 
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3.2.2 What Speeds the Drug Discovery Process? 
The Pharmaceutical Research and Manufacturers of America (PhRMA) estimates 
that approximately $0.8 ~ $1 billion is required to bring one successful product to 
market13.  The most crucial element to accelerate costly and lengthy drug development 
process is the early prediction of the candidate drug’s behaviour for its absorption, 
distribution, metabolism, excretion and toxicity (ADME/Tox) as well as improvement on 
target identification and validation.  In order to comply with these demands, the drug 
R&D has been focusing on new areas of science using various in vitro, in vivo, and in 
silico methods and models. 
3.2.3 Potential Bottlenecks during the Drug Discovery Process 
One of the most critical bottlenecks during the drug discovery process is the hit-
to-candidate stage, which is an iterative process between chemistry and biology to find 
the drug candidate for later stages of drug development (Anon, 2002; Clark, 2003).  Over 
the last decade, due to advancement in the genomic and proteomic research, we know 
much more about types of the drug targets, but not their biological functions or pathways.  
In order to eliminate the bottleneck, the interaction between the drug and its potential 
targets must be established, and anti-targets must be eliminated to speed up the drug 
candidate selection process.   
Another possible bottleneck is establishing the ADME/Tox of new drug 
candidates on the established drug targets.  This has become increasingly crucial for the 
success of later drug development stages, especially during clinical trials.  Since failures 
                                                 
13 Drug Discovery and Development, PhRMA Publication, February 2007 
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in clinical trials are much more expensive and damaging, biotech and pharmaceutical 
companies are willing to spend extra to sort out early failures.   
The bottlenecks above can be eliminated by implementing combinatorial 
chemistry and high throughput screening for biological targets and drug leads.  However, 
most biotech and pharmaceutical companies do not have the expertise or in-house 
programs to fully utilize these innovative technologies.  Therefore, to keep up with these 
novel technologies and to identify potential drug compounds more efficiently, companies 
often turn to outsourcing, which also saves on the over all drug development cost.  As 
one of the senior scientists from Bristol Myers Squibb mentioned14, “Outsourcing has 
become so paramount in a pharmaceutical’s infrastructure and drug discovery strategy 
that it can no longer be considered an option.” 
3.3 Outsourcing the Drug Development Process 
More biotech and pharmaceutical companies are moving in the direction of 
outsourcing their preclinical and clinical research during drug development.  The 
worldwide drug discovery outsourcing market reached $5.4 billion in 2007, which 
increased 15% from $4.1 billion in 2006.  It is expected that the market will grow to 
exceed $8 billion in 2010 based on market research15.  The compound annual rate of the 
market is 16%, reaching almost $14 billion in 201316. 
                                                 
14 Quoted from Dr. Arvind Mathur’s speech at PABORD 06: The Pharmaceutical & Biotech Outsourcing, 
Research & Development Expo & Conference, London, UK (September 13 – 14, 2006) 
15 Source: Outsourcing in Drug Discovery, 3rd Edition, MarketResearch.com 
16 Ibid. 
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3.3.1 Why Outsource? 
The number of new molecular entities (NMEs) filed has been dropping 
precipitously over recent years (See Figure 3-4) despite steady and significant increases 
in R&D spending of biotech and pharmaceutical companies (Table 3-3).  The number of 
NMEs was 53 in 1996, which was an historical high, and dropped to 17 in 2007 while 
global R&D spending has doubled within the period (from $35 billion in 1996 to $77 
billion in 2007).  The general view of the industry is that the pharmaceutical industry 
must find ways to cut the drug discovery time by prioritising projects that are more 
promising in order to improve the efficiency and productivity of the R&D programs.  Of 
many business models to accomplish these goals, such as M&A, in-licensing, and 
strategic partnerships, the outsourcing model has been the most successful option to 
improve R&D productivity and reduce the costs.   
There are several benefits to outsource, especially for a small size biotech 
company.  Those benefits are: 
• Cost savings 
• Access to talent and new emerging technology 
• Compressed timelines 
• Increased production 
• Flexible resource planning 
Flexible resource planning due to outsourcing is a result of the other benefits, which 
allows biotech and pharmaceutical companies to allocate their resources more efficiently.  
This is the most important aspect of outsourcing, as outsourcing can provide a flexible 
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pool of resource, allowing the company to reduce wide swings between uptime and 
downtime of their resources, and thus, to maintain a steady-level of resource. 
 
Figure 3-4  Number of NMEs Filed Worldwide from 1996 to 200717 
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3.3.2 What Not to Outsource? 
There are several things to be considered before outsourcing any drug 
development activities.  Those are: 
• Intellectual property protection 
• Confidential information and trade secrets 
• Fraud and corruption 
• Meeting regulatory compliance demands 
                                                 
17 Chart created by author, with data from: Ibid. 
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• Geographical distance 
All the factors above are preventable by applying a good work ethics and an 
unambiguous company policy.  Thus, it is vital for a CRO to recognize these factors and 
proactively manage the company’s reputation and relationships to minimize any negative 
perception to the customers. 
3.3.3 Contract Research Organizations 
The main goal of CROs is to provide flexible capacity or complementary 
capabilities for the sponsoring company.  Pharmaceutical and biopharmaceutical 
companies of all sizes have been hiring contract research organizations (CROs) to 
outsource their drug development process18.  Nowadays, it is possible for biotech and 
pharmaceutical companies to hire CROs to carry out any stage of the drug development 
process, as the CRO market has become a one-stop shop full of expertise from diverse 
fields.     
3.3.4 Outsourcing Trend of High-throughput Screening 
High-throughput screening (HTS) is the automated, simultaneous testing of 
thousands of distinct chemical compounds in models of biological mechanisms.  Active 
compounds identified through HTS can provide the starting point in the design of 
powerful research tools that allow pharmacological probing of basic biological 
mechanisms, and which can be used to establish the role of a molecular target in a disease 
process, or, its ability to alter the metabolism or toxicity of a therapeutic agent.  Of the 
$5.4 billion spent on outsourcing the drug discovery process, outsourcing of high-
                                                 
18 For drug discovery phase, there are four phases: 1) Target identification, 2) target validation, 3) high-
throughput screening and 4) lead optimization. 
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throughput screening took 9% of the total market, about $500 million in 2007.19  
Increasing at a steady annual compound growth rate of 6%, the overall HTS market will 
grow to $720 million in 2013 (See Figure 3-5). 
Figure 3-5  Worldwide Screening Services Market growth in Revenues (2005 – 2013)20  
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3.4 Estimated AED HTS Market Potential 
Based on the market analysis of the overall HTS outsourcing of pharmaceutical 
companies, it can be concluded that approximately 10% of the drug sales for AEDs will 
                                                 
19 Source: Kalorama Information 
20 Chart created by author, with source: ibid.  
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be allocated to the AED drug discovery21.  Since the preclinical/animal testing of drug 
candidates takes upto 42% of the overall drug discovery effort, it is concluded that C-
Motions’ potential AED HTS market size can be optimistically estimated to be $200M 
worldwide based on the total AED sales of $5.21B in 2010.   
                                                 
21 Overall worldwide pharmaceutical sale is estimated to be $900B in 2008 while the R&D budget is $77B 
with 10% annual increase.  Thus, approximate budget allocation for the drug discovery would be 10% 
with a conservative estimation. (source: http://www.medicalnewstoday.com/articles/8875.php) 
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4:  COMPETING TECHNOLOGIES 
There are several different technologies on the market to measure efficacy and 
toxicity of AED candidates during the discovery/preclinical stage of drug development.  
Each technology has its own advantages and weaknesses.  C-Motions recognizes these 
factors for the technologies, which will potentially compete with C-Motions’ AED HTS 
technology.  The technologies that might be the contenders against C-Motions’ are 1) 
rodent models, 2) fruit fly models, 3) zebra fish models, and 4) in vitro models. 
4.1 Rodent Models 
A rodent model for the AED efficacy testing has been a gold standard for the 
biotech and pharmaceutical companies who actively look for a potential compound for 
treating epilepsy.  The model is somewhat advantageous and one of the closest 
comparables to the human brain.  There have been several approaches in recent years so 
that rodents could mimic human brains as closely as possible with help of genetic 
modifications (e.g. EpiMouse™22).  Rodent models in general, however, require 
individual preparation of the lab animals for testing AEDs, which incurs high R&D costs, 
and are not suitable for high throughput screening of multiple potential AED compounds. 
                                                 
22 Neurofit Preclinical Research, www.neurofit.com 
 Confidential 27
4.2 Fruit Fly Models 
A patent23 has been granted for a fruit fly model to screen potential AEDs.  The 
detail of the invention relates to a method for screening AEDs using a common fruit fly 
(Drosophila melanogaster) by generating mutations in the genes to induce epileptic 
seizures in male flies, which show leg-shaking motions.  By measuring a reduced 
intensity of leg shaking, efficacy of a potential AED can be tested under 
stereomicroscope.  The model has a potential merit to be used as a high throughput 
screening method.  However, fruit flies have limitation when human AEDs are tested on 
them because their ADME/Tox studies cannot reveal comparable results to humans.  In 
addition, other types of disorders, not exclusively due to epileptic seizures, can 
potentially cause their leg shaking movements, which could cause false negative results. 
4.3 Zebra Fish Models 
Zebra fish (Danio rerio) has been touted as a well-characterized model organism 
for potential AED screening, which provides invaluable whole organism in vivo data that 
is relatively close to humans.  The model was developed by a group of scientists 
(Baraban, Taylor, Castro, & Baier, 2005; Berghmans, Hunt, Roach, & Goldsmith, 2007) 
using a commercial motion detection video monitoring system by Noldus24.  DanioLabs, 
a UK based zebra fish drug discovery company, was the pioneer of the technology to use 
the zebra fish model for searching active ingredients to treat human neurological 
disorders.  On March 22nd, 2007, VASTox plc, a UK biotech company, acquired 
DanioLabs for £15 million.  VASTox (now Summit plc) is a medium sized drug 
                                                 
23 US Patent 6291739 
24 Noldus EthoVision XT Zebrafish larvae activity monitoring system 
http://www.noldus.com/site/doc200711027 
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discovery company, which has a broad set of clinical, pre-clinical, and discovery 
programmes for the treatments of serious disease areas with highly unmet medical needs.  
The zebra fish AED screening platform is amenable to high throughput analysis using an 
automated tracking system to measure the amount of movement induced by exposure to 
PTZ.  The company is currently testing the possibility of using the system to screen the 
library for potential AEDs25. 
4.4 In Vitro Models 
There are several in vitro methods available to screen AED candidates such as 
measuring cell-swelling response26, molecular targets and genetic mark-up testing.  In 
vitro testing, however, is not likely to replace screening in animal models because in vitro 
systems cannot model the specific pharmacodynamic actions required for seizure 
protection, and do not assess bioavailability and brain accessibility. 
4.5 C-Motions’ Technology versus Others 
All the technologies mentioned above show their unique attributes that are 
valuable during the drug development process since they are comparably effective to 
detect efficacy of AED candidates with their own usefulness.  However, when it comes 
down to scalable, hit-to-candidate, or ADME/Tox testing with a possibility of HTS 
implementation, C-Motions’ technology stands out as it covers the widest spectrum of the 
capabilities during the AED research (See Figure 4-1).  In addition, it could cover the 
longest timeframe during the drug discovery/preclinical period because of its HTS and 
animal-based screening aspects.  It is also superior to zebra fish, which could be capable 
                                                 
25 Zebrafish Screening by Summit plc http://www.summitplc.com/Zebrafish%20screening.htm 
26 US Patent 5902732 
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of HTS implementation, as Xenopus laevis shows a much more distinctive seizure pattern 
than Danio rerio, and thus, reduces potential errors or false positive results.   
Figure 4-1  Comparison of the Competing Technologies with C-Motions’ AED HTS 
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5:  C-MOTIONS’ STRATEGY 
5.1 SWOT Analysis of C-Motions 
C-Motions acknowledges the currently competitive HTS market in the drug 
development process.  The SWOT (Strength-Weakness-Opportunity-Threat) analysis of 
C-Motions is to identify the key internal and external variables to evaluate the strategic 
objectives.  The internal variables are divided into the strengths and weaknesses of C-
Motions to determine the impacts of those variables to the company.  The external 
variables are evaluated for the opportunities and threats from the outside of the company 
to establish a basic understanding of the business environment.  Based on the analysis, C-
Motions will strategize its business and product development, as well as its exit path.   
5.1.1 Internal Environment 
C-Motions is uniquely positioning itself in the value chain of the drug 
development process as its technology covers a wide range during drug 
discovery/preclinical process.  While there are many opportunities, the company also 
expects to see many different challenges.  First, the notable strengths of C-Motions that 
have been identified are: 
• Strong science and technology 
• Knowledge and capability of the founders in science and technology 
• Well-established network within the epilepsy research in North America 
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However, the weaknesses of C-Motions have been also recognized in tackling the 
challenges ahead.  Those are: 
• Uncertain financial backing 
• Still in-progress IP process 
• Lack of geographical presence other than Vancouver 
• Inexperience of the management team 
The identified weaknesses are incorporated into the business development and sales, risk 
management, exit strategies of C-Motions with corresponding action plans. 
5.1.2 External Environment 
The external environment will always be a mixture of diverse opportunities and 
threats.  It is a task for C-Motions’ management team to understand the external 
environment and to identify current and potential opportunities and threats.  The 
identified opportunities for C-Motions are: 
• Emerging HTS market 
• Public awareness of epilepsy 
• Value chain approaches of biotech companies 
• Fast growth in the CRO market 
• Growing trends in Preclinical studies27 
                                                 
27 One of the most notable current trends in the biotech sector is trading data from pre-clinical and clinical 
studies.  One of the examples of data trading is hiring a CRO during any stage of drug development.  C-
Motions will fully exploit the current trend by serving specialized segment of the AED discovery 
process for biotech and pharmaceutical companies. 
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There are major threats that C-Motions will encounter during the business launch.  
The imminent threats from the external environment to C-Motions are: 
• Other comparable or alternative technologies 
• Strong buyer power by biotech and pharmaceutical companies 
• Slow adoption of its concept and technology.  
Among these threats, the slow adoption of the technology can be seen as the most 
significant issue to deal with to create the AED HTS market in the biotech industry due to 
the newness of the technology.  In order to facilitate adoption of the technology, C-
Motions will use a push strategy that involves strong sales and marketing effort. 
5.1.3 SWOT Analysis 
Based on the internal and external environments identified, the SWOT analysis of 
C-Motions has been formulated (Figure 5-1).  From the SWOT of C-Motions, it is 
possible to strategize the company’s direction using the Search, Avoid, Exploit, and 
Confront action plans.  As a small startup, C-Motions’ strongest assets are its technology, 
academic network, and the people involved, on which the company should focus with 
maximum effort.  On the other hand, at this stage, it would be wise to avoid any activity 
that may cause extensive cash expenditure, such as any legal battle with a competitor.     
 
 Confidential 33
Figure 5-1  SWOT Analysis of C-Motions 
 
5.1.4 Success Factors 
In order for C-Motions’ business to be successful, it must satisfy the overall needs 
of an effective HTS Screening assay for its core services and products.  These needs are 
to establish: 
• Stability and reliability of the HTS screening assay 
• Biological relevance of the assay, which is capable of detecting novel molecular 
interactions 
• Kinetically valid assay that can predict how the compound and target will interact 
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The objectives above can be primarily obtained by having biochemical expertise, assay 
development professionals, ability to produce relevant biological models, access to 
reagents and support services, and own robotic systems that are in-house and validated 
for drug screening.  In addition, in conducting its business as a CRO, C-Motions must 
focus on achieving excellence in confidentiality, quality and timeliness among many 
factors (Figure 5-2), which have been identified as the leading decision making points by 
the biotech and pharmaceutical companies who wish to outsource their drug development 
process. (Roth, 2007).  
Figure 5-2  Factors Involved in Making Outsourcing Decisions28 
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28 Chart created by author, with data from: Contract Pharma: 2007 Annual Outsourcing Survey, May 2007 
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5.2 Business Development and Sales Strategy 
The following business model has been devised based on the SWOT analysis of 
C-Motions.  It focuses on speed to market for early revenue generation with positive cash 
flow, establishment of market presence, and refinement/expansion of the core technology.  
5.2.1 Business Model 
C-Motions will start out its business by offering services to biotech and 
pharmaceutical companies for AED screening of candidate compounds.  The biotech and 
pharmaceutical companies will physically send their AED candidates to C-Motions 
laboratory, which screens potential AEDs for toxicity and efficacy.  The resulting data 
will be sent to the biotech or pharmaceutical company for further analysis by an 
encrypted online packet or by registered mail.  Following service contracts, C-Motions 
will move toward establishing a relationship with a strategic service partner of the 
neurotherapeutic areas, such as J&J, Shire Pharmaceuticals, or Neurochem, Inc, which 
have well-established presence in the related area.  The initial aim for the business model 
is to expedite the adoption of C-Motions’ technology as well as to generate a positive 
revenue growth in the early stage of the business establishment.   
5.2.2 Customer Profiles 
In the biotech service industry, successful products and services enter the market 
through a similar pattern to a new technology product.  Influential “early adopters” who 
are the voices of the industry first use a new innovative service.  For this reason, C-
Motions’ first line of customers will be the biotech and pharmaceutical companies who 
are actively pursuing AED development, such as Johnson & Johnson and Shire 
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Pharmaceuticals Group plc.  In addition, there are number of small academic laboratories 
that are actively searching for potential AEDs, on which C-Motions can concentrate its 
early sales efforts.   
5.2.3 Sales Channels 
The recommendation of C-Motions’ services will be commenced by a talented 
group of direct sales force, whom C-Motions will begin hiring in 2010.  A competitive 
salary has been budgeted for direct sales personnel to attract experienced individuals with 
well-established neurotherapeutic networks.  The early sales team will consist of a small 
team of highly qualified sales representatives and service education specialists managed 
by the VP of Sales.  While sales representatives target biotech and pharmaceutical 
companies’ decision makers to use C-Motions’ AED Screening service, service education 
specialists provide necessary training and correct interpretation of the data after a service 
contract has been made.  This bilateral sales team approach has been adopted by many 
successful service based companies to increase service frequency and utilization, which 
will ensure ongoing sales of C-Motions’ services.  In the beginning, C-Motions is likely 
to focus on the North American market, as it has the highest market potential for the 
AED related sales (See Figure 3-1).  In the long term, however, the company has plans to 
establish a global presence of its sales effort since the CRO business model is less bound 
to its geographical location or proximity (See Figure 5-2). 
5.2.4 Pricing 
Since the HTS for AED candidate drugs is still in the proof of concept stage, it is 
challenging to determine proper pricing at this point.  However, there are several 
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comparable services (See Table 5-1 and Table 5-2) in the outsourcing market, which can 
be referenced to decide the initial price point of C-Motions’ HTS.  The prices of the 
screening services may be different depending on the types of services and regions; 
however, it is certain that the in vitro HTS is an order of magnitude less expensive than 
the in vivo service for similar experiments in general.  The pricing strategy of C-Motions’ 
HTS will be based on adding-on options as the technology becomes more refined.  The 
service will start at $100 per compound for its first basic efficacy test on potential AED 
compounds with cGLP complying data and standard.  The service will offer more 
biological assays options depending on capability of the HTS platform at higher prices. 
Table 5-1 in vitro HTS Assay Kits in the Market29 
Company Service Price
Biocompare TACE HTS Assays $442 for 96 Tests
McGill Life Science Automated acquisition and 
analysis imaging system
$15 per screen of plate 
of 80 compounds
Rockefeller University Library Screen with Post 
Screen Assistance
$12,150 for External 
Users
Invitrogen Ion Channel Biology Assay 
kits
$270 - $5,600 for 100 
plates  
Table 5-2 Price Comparison between in vitro and in vivo Anti-Cancer Drug Screenings30 
Service Price
In vitro anti-cancer drug 
screening and evaluation
One drug (five different doses) using one cancer 
cell line costs $600
In vivo anti-cancer drug 
screening and evaluation
One drug (three different doses) using one cancer 
cell nude mice xenograft model costs $12,000
Acute toxicity evaluation One drug costs $3,000.  
                                                 
29 http://www.biocompare.com/matrix/17989/TACE-Assays-(High-Throughput-Screening).html; 
http://www.lifesciencescomplex.mcgill.ca/hts-hcs/fees;  
http://www.rockefeller.edu/highthroughput/pricing.php; 
http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Drug-Discovery/Target-
and-Lead-Identification-and-Validation/Ion-Channel-Biology.html 
30 http://www.keygentec.com/service.aspx (Nanjing KeyGen Biotech. Co. Ltd)  
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5.3 Product Development Strategy 
C-Motions’ service based launch strategy focuses on maximum exploitation of the 
current technology in the early part of the business launch.  In addition, C-Motions will 
develop different models of the platforms that use the same core technology in order to 
satisfy the unmet needs for whom would like to pursue the screening process 
independently.  Main target customers are the biotech and pharmaceutical companies that 
value confidentiality of information and are capable of integrating C-Motions’ 
technology to their unique research platforms. 
5.3.1 Engineering R&D/Prototyping 
C-Motions Biotechnology has a connection to Dr. Edward Park, the director of 
the newly established Lab for Applied Control and Bio-Robotic Systems (LACOBS) in 
Victoria, Canada.  Dr. Park’s research is inherently multidisciplinary, encompassing a 
number of fields in engineering and science.  Focuses in his biomedical research are the 
invention and development of new biomedical research tools or techniques, or the 
improvement on existing tools/techniques.  This connection will allow C-Motions to 
develop a research platform that can automatically screen potentially efficacious AED 
candidates that can be forwarded to further non-clinical or clinical studies.   
5.3.2 Additional Product Development 
In the beginning, the platform will be aimed for the in-house operation for HTS.  
Thus, the platform will suffice to have more complex features and sophisticated functions 
with less explicit instructions for the in-house engineers.  As the adoption of the HTS 
technology progresses, however, C-Motions will seek for opportunities to sell the 
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platform as a product.  That shall require the platform to be adequately ‘packaged’ for its 
marketing and sales as an independent unit.  The initial targets for the product will be 
biotech and pharmaceutical companies, who would prefer their own in-house HTS to 
outsourcing HTS operations for the reasons to achieve economy in operations and/or, 
more importantly, to protect their confidential drug development process.  C-Motions 
AED HTS Platform will be refit to be robust and easy to operate with basic instructions 
and manuals.  The platform will also be coupled with consumables for the convenience of 
HTS by a third party.   
5.4 Intellectual Property 
The C-Motions team is currently under provisional patent filing process through 
the UBC UILO.  The cost of the patent filing process and related work will be covered by 
UBC once the UILO decides to proceed to file the patent.  The final agreement between 
C-Motions and other related institutions has not been established at this point.  In any 
case, a broad US patent filing with international extension coverage is expected, which 
will protect the company for its methods of conducting the AED HTS process, image 
generation and computer pattern recognition, and the company’s proprietary algorithm 
that manages the overall HTS process and data handling.  The company also understands 
that the patent is only the first step to protect C-Motions’ IP, not the last.   
Having the UBC UILO is advantageous in many aspects, as it has been known to 
be successful at facilitating the exchange of knowledge between the institution and the 
wider community.  The company will use this opportunity to create a strong network of 
potential collaborators from the industry, which will promote its IP and related 
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technologies.  In addition, the relationship will enable the company to leverage its IP to 
execute its business strategy. 
Once the UBC UILO agrees to participate in this venture, it can further help the 
company to promote the service and product to a wider range of customers.  The 
institution can also help us to negotiate with other biotech or pharmaceutical companies 
as well as to design patent strategies that ensure quality product delivery to those most in 
need, while securing a sustainable local infrastructure.   
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6:  RISK AND EXIT STRATEGY 
6.1 Key Risks 
Patent Approval: Since C-Motions’ platform technology is still under review for the 
provisional patent, there is a possibility that the patent process could be delayed.  
Although not innovative or effective as C-Motions’ AED HTS technology, there are 
competing technologies in the market.  Since the HTS market is expanding rapidly, C-
Motions is to position itself as the first mover to establish its reputation and brand by 
entering the market as quickly as possible.   
Risk management – In order to mitigate the risk, C-Motions’ management team has been 
working with the UBC UILO personnel to follow the ongoing patent filing efforts.  In 
addition, it is important to note that a patent is to exclude competitors from using the idea.  
Therefore, it is extremely important for the C-Motions’ management team and the UBC 
UILO to identify the gist behind C-Motion’s technology that differentiates its innovation 
from other technologies. 
Management Risk: C-Motions recognizes that, in the future, the company needs to bring 
on additional management.  For example, an industry seasoned CEO will be required to 
coordinate the intricacies of the product development of the technology and a final go-to-
market strategy. 
Risk Management – All members of the management team are willing to work with C-
Motions’ investors to find suitable management candidates for key roles when the 
company grows to a level of sophistication beyond the scope of current management. 
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6.2 Exit Strategy 
There are three main exit scenarios for C-Motions based on the internal and 
external environment. The scenarios that the C-Motions Management Team is 
investigating are:  
• Out-licensing the proprietary technology 
• Selling the company, joint venture or M&A 
• Early IPO 
At this moment, out-licensing the technology is the least feasible option.  To be 
evaluated fairly, C-Motions should be viewed as a synergistic entity that is capable of 
conducting business, not only with its technology, but also with a strong management 
team and a sound business strategy.  In addition, the amount of royalties from licensing 
the technology is usually a small fraction of the company’s value, not to mention losing 
control over its core technology, which is one of the most important assets.   
The current ideal exit path is an early IPO (in Year 7) of the company in order to 
capture the full value of the company.  The company’s revenue is predicted to be $15M 
in year 7, which is not adequate for NASDAQ, which requires a higher revenue range 
(over $75M) to be a successful IPO (Rosenberg, 2007).  Hence, C-Motions will look for 
an opportunity to be listed on the TSX, which is a relatively small capital market, but is 
closer to the Canadian investors.  In any case, C-Motions will prepare its IPO by focusing 
on generating strong revenue and maintaining positive cash flow with the company’s 
solid IP portfolio.   
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In case of selling the business or doing a joint venture, C-Motions will look for 
major pharmaceutical companies as potential buyers or partners so that the AED HTS 
platform technology can be further developed into a larger commercial scale that can 
bring economies of operation through the resources of a large pharmaceutical company.  
Ideal candidates for the purchasers in the pharmaceutical companies would be J&J, P&G, 
Shire Pharmaceuticals, and Neurochem, Inc who have had the dominant presence in the 
AED development.  These companies have their own brands of AEDs that became 
generic or will become generic in the near future, which will make C-Motions’ 
technology attractive to their AED and related neurological R&D programs.   
 Confidential 44
7:  FINANCIALS 
7.1 Assumptions 
There are several financial assumptions recognized for C-Motions’ business: 
1)  Sales Volume:  Conventional rodent model drug screening can be time-consuming 
and labour intensive; however, due to its value to the AED research, the market for 
conventional rodent model drug screening will sustain as is.  C-Motions conservatively 
estimates its innovative AED Screening Platform to capture 0.25% of the total market for 
the potential AED screening market worldwide in 2011 upon its introduction. The 
worldwide market penetration of C-Motions’ AED Screening Platform technology is 
estimated to grow to approximately 2% by 2013 by adding more sales channels and 
finding reputable R&D partners for drug discovery worldwide.  
2)  Median yearly incomes used31:  A 35% markup is applied to salaries to cover taxes, 
benefits (25% of the incomes), profit sharing and stock options for the employees of C-
Motions.  
3)  Revenue and Pricing:  C-Motions’ service is priced at $100 CAD per compound for 
basic toxicity and efficacy testing.  The premium service will be priced at $500 CAD per 
compound, which will provide more details of information with options of tailoring to 
customers’ needs including toxicity and efficacy checks. 
                                                 
31 Source: Canada Revenue Agency 
 Confidential 45
4)  Rates:  The Canadian inflation rate is 2% per year, the discount rate is 30%, the long-
term growth rate is 5%, and the overall corporate tax rate is 30%32 with tax paid at the 
beginning of the next fiscal year. 
5)  Market Growth:  The world HTS market is estimated to grow at 6% through 2013.  
The customer adoption rate of C-Motions’ service assumes the sales revenue reaching 
50% a year after introduction, growing at the same rate for 2 years and then growing at a 
slower 25% in 4 years. 
6)  Other factors:  In Canada, many government incentives are offered to a R&D based 
company for business development.  Besides the SR & ED tax credits that function 
similarly to grants, other grants are also offered by the National Research Council of 
Canada through the industrial Research Assistance Program, Technology Partnerships 
Canada and Government Assistance Programs for S&T Research.  C-Motions is aware of 
these unique opportunities and intends to seek them for extended funding.   
7)  Investor IRR and Exit Value:  Exit value is calculated based on a 10x EBITDA 
multiplier, on the conservative side of recent available comparable data in the biotech 
industry33. 
7.2 Start-up Investment and Equity Structure 
C-Motions’ start-up costs are estimated at $550,000 CAD in total.  The initial 
fifty thousand will be paid for the patent and administrative fees by the founders, while 
the remaining $500,000 CAD for the first-wave of the product development will be 
funded by seed round funding.  In 2010, a Series A offering of $1,500,000 will allow the 
                                                 
32 Source: KPMG in Canada, Canadian Corporate Income Tax Rates 
33 Biotech industry average LTM Sales Multiple = 28.5 (Source: FactSet and Public Company Filings) 
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completion of C-Motions’ initial marketing and sales for the AED HTS services.  In 
order to fund the second-wave of the product development and marketing, C-Motions 
will seek a Series B round of $2,500,000 CAD in 2012 from different sources or series A 
investors as part of the Series A round. 
7.3 Investment Requirements and Return Potential 
C-Motions is currently raising a $500,000 Seed investment.  This investment 
offers Seed investors an outstanding 77% IRR with a 30% final equity stake (after Seed 
conversion of a one year, 120% yield note).  In 2010, C-Motions will offer Series A 
shares for additional $1.5M.  Series A investors will enjoy a 54% IRR with a 25% equity 
stake.  An employee option pool of 5% equity (final dilution) is available for incentive 
stock options.  The co-founders will own a 24% equity stake after all financing rounds.  
Liquidity will be realized by year 7 of operations (2015). 
7.4 Pro Forma Financials 
C-Motions will begin formal marketing efforts in early 2010 after academia and 
local reviews for the basic service and related data analysis.  The forecasted numbers of 
new customers is 25 by direct sales in 2010.  The numbers will grow to 50 in 2011.  
Projected gross margin for C-Motions service is over 30% including its maintenance and 
related labour.  The physical parts of the C-Motions platform construction will be built in 
house.  Initially the company will offer 2% sales commission for the direct sales, which is 
subject to increase later depending on the scale of sales.  In the beginning of the sales, 
marketing will be targeted at major biotech companies allowing the company to focus on 
efficient advertising in scientific journals and academic conferences.  Accounts 
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receivable is estimated to be 30% of the total goods sold and anticipated not to be 
realized at 30 days from delivery to reimbursement.  The net income of C-Motions will 
reach over $7M by year 8 with the previous assumptions (See Figure 7-1).  
As an investment opportunity, C-Motions offers outstanding opportunity to 
potential investors.  As one of the examples displaying its potential, by the third year of 
sales, 2013, C-Motions will achieve a ROA of 37% and ROE of 44%, which will be close 
to double in the following year.  The company expects to be cash flow positive by 2013 
with significant cash generation and market penetration leading to an exit in 2015 (See 
Figure 7-2). 
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Figure 7-1  C-Motions’ Net Income Grows to Over $7 Million by Year 8 
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Figure 7-2  C-Motions’ Free Cash Flow and Year End Cash Position 
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8:  CONCLUSION 
C-Motions’ breakthrough anti-epilepsy drug high throughput screening 
technology is likely to produce rapid growth of shareholder value, leveraging a small 
amount of equity capital to grow by $15M/year, and the company is likely to become a 
highly profitable business within six years with an exceptionally high net margin of 32%.  
C-Motions’ business has outstanding characteristics: 
• An exclusive $200 million potential world market, currently underpenetrated due 
to the limitation of existing technologies that C-Motions’ Anti Epilepsy Drug 
(AED) High Throughput Screening (HTS) service overcomes 
• A well fitted, compelling solution to the high cost of the AED development by 
biotech and pharmaceutical companies worldwide 
• Capable management team combining scientific, engineering and business 
expertise 
• Easily targeted major customers in the biotech industry with a history of early 
technology adoption 
• Potential of generating recurring revenues from exceptionally high-margin, and 
high volume sales of consumables for the next generation of product development 
• Small capital requirements relative to market size 
• Potential for profitable exit through sale of company or IPO within seven years 
• C-Motions solves a high cost problem for biotech and pharmaceutical companies. 
Currently C-Motions seeks $500K seed investment to fund product development.  
Two subsequent venture rounds of $1.5M and $2.5M will fund the commercialization 
and marketing of the technology.  C-Motions offers a unique opportunity to the investors 
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who would like to enjoy  great financial returns, as well as a chance to contribute to C-
Motion’s commitment to find cures for the incurables.   
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APPENDICES 
Appendix I: Forecasted Income Statement, Cash Flow, Balance Sheet 
Projected Yearly Income Statement (2009 to 2016)
2009 2010 2011 2012 2013 2014 2015 2016
Sales Volumes
Direct Sales
C-Motions AED HTS Basic Service -                        -                        2500 5000 10000 15000 22500 33750
C-Motions AED HTS Premium Service -                        -                        500 1000 2000 3000 4500 6750
C-Motions AED HTS Platform -                        -                        0 0 5 10 20 30
C-Motions AED HTS Consumables -                        -                      0 0 5000 10000 20000 30000
Total Sales Revenues -                        -                        $500,000 $1,000,000 $4,625,000 $8,250,000 $15,000,000 $22,500,000
Total Cost of Goods Sold -                        -                        $50,000 $100,000 $462,500 $825,000 $1,500,000 $2,250,000
Contribution Margin -                        -                        $450,000 $900,000 $4,162,500 $7,425,000 $13,500,000 $20,250,000
Contribution Margin % 0% 0% 90% 90% 90% 90% 90% 90%
Operating Expenses
Salary Expenses ($112,500) ($325,000) ($762,500) ($993,750) ($1,353,125) ($1,525,000) ($2,287,500) ($3,431,250)
Commission Expenses (Total) $0 $0 ($10,000) ($20,000) ($92,500) ($165,000) ($300,000) ($450,000)
Total Employee Expenses ($112,500) ($325,000) ($772,500) ($1,013,750) ($1,445,625) ($1,690,000) ($2,587,500) ($3,881,250)
Facilities Rent ($5,000) ($25,000) ($75,000) $500,000 $625,000 $781,250 $976,563 $1,220,703
Administrative Expenses ($11,250) ($32,500) ($77,250) ($101,375) ($144,563) ($169,000) ($258,750) ($388,125)
Marketing Expenses $50,000 $500,000 ($75,000) ($150,000) ($693,750) ($1,237,500) ($2,250,000) ($3,375,000)
R&D Expenses ($20,000) ($50,000) ($120,000) ($250,000) ($475,000) ($1,250,000) ($1,500,000) ($2,250,000)
Insurance ($5,000) ($10,000) ($35,000) ($120,000) ($180,000) ($200,000) ($250,000) ($312,500)
SR & ED Tax Credits (provincial) $2,000 $5,000 $12,000 $25,000 $47,500 $125,000 $150,000 $225,000
SR & ED Tax Credits (federal) $7,000 $17,500 $42,000 $87,500 $166,250 $437,500 $525,000 $787,500
Total Operating Expenses ($94,750) $80,000 ($1,100,750) ($1,022,625) ($2,100,188) ($3,202,750) ($5,194,688) ($7,973,672)
EBITDA (94,750)            80,000            (650,750)        (122,625)        2,062,313       4,222,250        8,305,313         12,276,328     
Depreciation ($10,000) ($70,000) ($80,000) ($100,000) ($125,000) ($175,000) ($245,000) ($350,000)
EBIT ($104,750) $10,000 ($730,750) ($222,625) $1,937,313 $4,047,250 $8,060,313 $11,926,328
Operating Margin -                        -                        -                        -                        -                        -                        -                        -                        
Interest Income (Expense) -                        -                        -                        -                        -                        -                        -                        -                        
EBT ($104,750) $10,000 ($730,750) ($222,625) $1,937,313 $4,047,250 $8,060,313 $11,926,328
Less loss carry forward -                        -                        ($94,750) ($825,500) -                        -                        -                        -                        
Provision for Income Tax ($31,425) $3,000 ($247,650) ($314,438) $581,194 $1,214,175 $2,418,094 $3,577,898
Net Income ($104,750) $7,000 ($730,750) ($222,625) $1,356,119 $2,833,075 $5,642,219 $8,348,430
Net Margins 0.00% 0.00% 0.00% -22.26% 29.32% 34.34% 37.61% 37.10%  
Projected Yearly Cash Flow Statement (2009 to 2016)
2009 2010 2011 2012 2013 2014 2015 2016
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8
Month Total Total Total Total Total Total Total Total
Cash Flows From Operations
Net Income (Loss) ($104,750) $7,000 ($730,750) ($222,625) $1,356,119 $2,833,075 $5,642,219 $8,348,430
  + Depreciation $10,000 $70,000 $80,000 $100,000 $125,000 $175,000 $245,000 $350,000
  (Inc.)/Dec. of Accounts Receivable -                      -                      ($150,000) ($300,000) ($925,000) ($1,650,000) ($3,000,000) ($4,500,000)
  (Inc.)/Dec. of Prepaid Expenses ($833) ($2,917) ($13,333) $23,333 ($1,458) ($20,313) ($64,453) ($111,816)
  (Inc.)/Dec. of Inventory -                      (16,667)           (33,333)           (115,625)         (206,250)         (375,000)         (562,500)         (562,500)         
  Inc./(Dec.) of Current Liabilities ($8,646) $4,792 ($81,229) ($64,594) $527,116 $1,147,904 $2,378,953 $3,504,051
Total Cash Flows From Operating ($104,229) $62,208 ($928,646) ($579,510) $875,526 $2,110,667 $4,639,219 $7,028,164
Cash Flows From Investing Activities
 Capital Expenditures ($50,000) ($300,000) ($50,000) ($100,000) ($125,000) ($250,000) ($350,000) ($525,000)
Total Cash Flows From Investing ($50,000) ($300,000) ($50,000) ($100,000) ($125,000) ($250,000) ($350,000) ($525,000)
Free Cash Flows ($204,229) ($537,792) ($1,028,646) ($779,510) $625,526 $1,610,667 $3,939,219 $5,978,164
Cash Flows From Financing Activities
  Angel Round, Convertible note $500,000 -                      -                      -                      -                      -                      -                      -                      
  Venture Round A 1,500,000       -                      -                      -                      -                      -                      -                      
  Venture Round B -                      -                      -                      2,500,000       -                      -                      -                      -                      
  Long Term Debt -                      -                      -                      -                      -                      -                      -                      -                      
  Government Grants -                      -                      -                      -                      -                      -                      -                      -                      
Total Cash Flows From Financing $500,000 1,500,000     $0 2,500,000     -                    -                     -                     -                    
Total Cash Flow $295,771 $962,208 ($1,028,646) $1,720,490 $625,526 $1,610,667 $3,939,219 $5,978,164
  Beginning Cash Balance $0 $295,771 $1,257,979 $229,333 $1,949,823 $2,575,349 $4,186,016 $8,125,234
Ending Cash Balance $295,771 $1,257,979 $229,333 $1,949,823 $2,575,349 $4,186,016 $8,125,234 $14,103,398  
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Projected Yearly Balance Sheet (2009 to 2016)
2009 2010 2011 2012 2013 2014 2015 2016
Cash & Cash Equivalents $500,000 $295,771 $1,257,979 $229,333 $1,949,823 $2,575,349 $4,186,016 $8,125,234
Accounts Receivable -                     -                     $150,000 $300,000 $925,000 $1,650,000 $3,000,000 $4,500,000
Prepaid Expenses $833 $2,917 $13,333 ($23,333) $1,458 $20,313 $64,453 $111,816
Stock/Inventory -                     $16,667 $33,333 $115,625 $206,250 $375,000 $562,500 $562,500
Total Current Assets $500,833 $315,354 $1,454,646 $621,625 $3,082,531 $4,620,661 $7,812,969 $13,299,551
Net Fixed Assets $50,000 $350,000 $400,000 $500,000 $625,000 $875,000 $1,225,000 $1,750,000
Accumulated Depreciation ($10,000) ($70,000) ($80,000) ($100,000) ($125,000) ($175,000) ($245,000) ($350,000)
Total Non-Current Assets $40,000 $280,000 $320,000 $400,000 $500,000 $700,000 $980,000 $1,400,000
Total Assets $540,833 $595,354 $1,774,646 $1,021,625 $3,582,531 $5,320,661 $8,792,969 $14,699,551
Accounts Payable ($8,646) $4,792 ($81,229) ($64,594) ($54,078) ($66,271) ($39,141) ($73,848)
Income Taxes Payable -                     -                     -                     $0 $581,194 $1,214,175 $2,418,094 $3,577,898
Total Current Liabilities ($8,646) $4,792 ($81,229) ($64,594) $527,116 $1,147,904 $2,378,953 $3,504,051
Long Term Liabilities -                     -                     -                     -                     -                     -                     -                     -                     
Total Liabilities ($8,646) $4,792 ($81,229) ($64,594) $527,116 $1,147,904 $2,378,953 $3,504,051
Paid In Capital $2,050,000 $2,050,000 $7,050,000 $7,050,000 $7,050,000 $7,050,000 $7,050,000 $7,050,000
Retained Earnings ($1,500,521) ($1,459,438) ($5,194,125) ($5,963,781) ($3,994,584) ($2,877,243) ($635,984) $4,145,500
Total Liabilities & Common Equity $540,833 $595,354 $1,774,646 $1,021,625 $3,582,531 $5,320,661 $8,792,969 $14,699,551
Fiscal Year Ending in December of
 
Appendix II: Profitability Ratios and Break Even Ratios 
2013 2014 2015 2016
90.00% 90.00% 90.00% 90.00%
37.85% 53.25% 64.17% 56.79%
44.38% 67.89% 87.97% 74.57%
2013 2014 2015 2016
679.65% 463.51% 369.62% 419.50%
640.52% 430.84% 345.97% 403.45%
369.90% 224.35% 175.96% 231.88%
Profitability Ratios & Break Even Ratios
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C-Motions will break even in 2015. 
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Appendix III: Proposed Capitalization Structure 
Category Paid In Capital # of Shares Ownership%
(Fully Diluted)
Founders $50,000 5000000 24%
Employee/Option Holders $0 1000000 5%
Seed Investors $500,000 6333333 30%
Series A Investors $1,500,000 5333333 25%
Series B Investors $2,500,000 3333333 16%
Total $4,550,000 20999999 100%  
Appendix IV: Valuation Table after Funding 
Valuation First Round Funding (2009) Second Round Funding (2010) Third Round Funding (2012)
Total Shares 6333333 5333333 3333333
Price Per Share $0.12 $0.37 $0.87
Pre Money Value* $973,684 $4,968,750 $15,750,001
Post-Money Value $1,473,684 $6,468,750 $18,250,001  
Appendix V: Internal Rate of Return 
Seed Series A Series B
2009 ($500,000) $0 $0
2010 $0 ($1,500,000) $0
2011 $0 $0 $0
2012 $0 $0 ($2,500,000)
2013 $0 $0 $0
2014 $0 $0 $0
2015 $15,314,594 $12,896,500 $8,060,312
IRR 77% 54% 48%
Exit Year 2015
Year
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Appendix VI: Employee Hiring Plan 
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X 1.25
G&A
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w/ benefits
CEO (founder)
$50,000
$62,500
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1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
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Accountant
$45,000
$56,250
-   
-   
-   
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0
-   
-   
-   
-   
0
1  
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
Secretaries
$30,000
$37,500
-   
-   
-   
-   
0
-   
-   
-   
-   
0
-   
-   
-   
-   
0
1  
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
Marketing & Sales
VP Sales & Bus. Dev.
$60,000
$75,000
-   
-   
-   
-   
0
-   
-   
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
Account & Product Manager
$55,000
$68,750
-   
-   
-   
-   
0
-   
-   
-   
-   
0
-   
-   
-   
-   
0
-   
-   
-   
-   
0
1  
1  
1  
1  
1
1  
1  
1  
1  
1
Product Ed. Specialists
$55,000
$68,750
-   
-   
-   
-   
0
-   
-   
-   
-   
0
1  
1  
1  
1   
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
Direct Sales
$70,000
$87,500
-   
-   
-   
-   
0
-   
-   
-   
-   
0
1  
1  
1  
1  
1
1  
1  
2  
2  
2
2  
2  
3  
3  
3
3  
3  
4  
4  
4
Customer Service
Field Engineers
$45,000
$56,250
-   
-   
-   
-   
0
-   
-   
-   
-   
0
-   
-   
-   
-   
0
-   
-   
-   
-   
0
1  
1  
1  
1  
1
1  
1  
2  
2  
2
R&D
Chief Scientific Officer (founder)
$65,000
$81,250
-   
-   
1  
1  
1
1   
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
Software Developers
$50,000
$62,500
-   
-   
-   
-   
1
1  
1  
1  
1  
1
1  
1  
2  
2  
2
2  
2  
3  
3  
3
3  
3  
3  
3  
3
3  
3  
3  
3  
3
Research Scientists
$40,000
$50,000
-   
-   
-   
-   
0
-   
-   
-   
-   
0
1  
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
Productions and Operations
COO (founder)
$65,000
$81,250
-   
-   
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
Engineering
$45,000
$56,250
-   
-   
-   
-   
1
-   
-   
-   
-   
1
1  
1  
1  
1  
1
1  
1  
2  
2  
2
2  
2  
3  
3  
3
3  
3  
4  
4  
4
Director of MFG.
$55,000
$68,750
-   
-   
-   
-   
0
-   
-   
-   
-   
0
-   
-   
-   
-   
0
-   
-   
1  
1  
1
1  
1  
1  
1   
1
1  
1  
1  
1  
1
QA/QC
$40,000
$50,000
-   
-   
-   
-   
0
-   
-   
-   
-   
0
1  
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
Purchasing
$40,000
$50,000
-   
-   
-   
-   
0
-   
-   
-   
-   
0
-   
-   
-   
-   
0
-   
-   
1  
1  
1
1  
1  
1  
1  
1
1  
1  
1  
1  
1
Total Employees
-  
-  
3
3
1.5
4
4
5
5
4.5
11
11
12
12
12
13
13
18
18
16
20
20
22
22
21
22
22
25
25
24
YEAR 5
YEAR 6
YEAR 1
YEAR 2
YEAR 3
YEAR 4
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Appendix VII: Proposed Pre-Money Valuation and Methodology 
Disc factor 70.00%
LT Growth Rate 5.00%
Year to exit 7
Per Plan VC
25% Discount
$5,642,219 $4,231,664
20 20
$112,844,375 $84,633,281
($45,137,750) ($33,853,313)
$67,706,625 $50,779,969
$1,650,018 $1,237,514
Home Run Double Single
$15,000,000 $7,500,000 $1,250,000
$5,642,219 $2,821,109 $470,185
20 15 10
$112,844,375 $42,316,641 $4,701,849
($45,137,750) ($16,926,656) ($1,880,740)
$67,706,625 $25,389,984 $2,821,109
41.0338673 41.0338673 41.0338673
$1,650,018 $618,757 $68,751
10% 50% 40%
$165,002 $309,378 $27,500
$501,881
Year After-tax Income PV Factor PV of Earnings 25% VC Discount
2009 ($104,750) 1.7 ($61,618) ($46,213)
2010 $7,000 2.89 $2,422 $1,817
2011 ($730,750) 4.913 ($148,738) ($111,554)
2012 ($222,625) 8.3521 ($26,655) ($19,991)
2013 $1,356,119 14.19857 $95,511 $71,633
2014 $2,833,075 24.137569 $117,372 $88,029
2015 $5,642,219 41.0338673 $137,502 $103,126
2016 $8,348,430 69.75757441 $119,678 $89,758
$235,474 $176,605
PV of NI >2016 $1,584,383 $1,188,287
Estimated PV $1,819,857 $1,364,893
Per Plan 25% VC Discount
$15,000,000 $11,250,000
2 2
$30,000,000 $22,500,000
($12,000,000) ($9,000,000)
$18,000,000 $13,500,000
41.0338673 41.0338673
$438,662 $328,997
Per Plan 25% VC Discount
$1,650,018 $1,237,514
$501,881 $376,410
$1,819,857 $1,364,893
$438,662 $328,997
$1,819,857
$328,997
$964,779
Multiple of Revenues
2015 Sales
Multiple of Revenues (a)
(Multiple of after-tax earnings)
First Chicago Method:
Estimated Value Today
Private Co. Discount (40%)
Estimated Value (2015)
Expected Present Value
After-tax Income (2015)
Conventional VC Valuation Model:
(Multiple of after-tax earnings)
Price/Earnings Multiple (a)
Average of 8 Values
Probability Factor
Estimated Value Today
PV Discount Factor
Private Co. Discount (40%)
Est. Value (2014 dollars)
PV Discount Factor (70%)
Estimated Value Today
Present Value of Future Net Income (NI) Streams
Multiple of Revenues
Maximum Valuation
Minimum Valuation
Present Value of Future Net Income (NI) Streams:
Summary of Valuation Methods Listed Above:
Conventional VC Valuation Model
First Chicago Method
Sum of Expected Values  =Estimated Present Value
Estimated Value (2015)
Private Co. Discount (40%)
Estimated Value (2015)
Price/Earning Ratio
After-tax Profits
Revenue (2015)
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